366 related articles for article (PubMed ID: 28295504)
1. Testosterone therapy has positive effects on anthropometric measures, metabolic syndrome components (obesity, lipid profile, Diabetes Mellitus control), blood indices, liver enzymes, and prostate health indicators in elderly hypogonadal men.
Canguven O; Talib RA; El Ansari W; Yassin DJ; Salman M; Al-Ansari A
Andrologia; 2017 Dec; 49(10):. PubMed ID: 28295504
[TBL] [Abstract][Full Text] [Related]
2. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.
Yassin DJ; Doros G; Hammerer PG; Yassin AA
J Sex Med; 2014 Jun; 11(6):1567-76. PubMed ID: 24712761
[TBL] [Abstract][Full Text] [Related]
3. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study.
Haider A; Saad F; Doros G; Gooren L
Obes Res Clin Pract; 2014; 8(4):e339-49. PubMed ID: 25091355
[TBL] [Abstract][Full Text] [Related]
4. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
[TBL] [Abstract][Full Text] [Related]
5. Effects of testosterone replacement therapy on metabolic syndrome among Japanese hypogonadal men: A subanalysis of a prospective randomised controlled trial (EARTH study).
Shigehara K; Konaka H; Nohara T; Izumi K; Kitagawa Y; Kadono Y; Iwamoto T; Koh E; Mizokami A; Namiki M
Andrologia; 2018 Feb; 50(1):. PubMed ID: 28497534
[TBL] [Abstract][Full Text] [Related]
6. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
Giagulli VA; Carbone MD; Ramunni MI; Licchelli B; De Pergola G; Sabbà C; Guastamacchia E; Triggiani V
Andrology; 2015 Nov; 3(6):1094-103. PubMed ID: 26447645
[TBL] [Abstract][Full Text] [Related]
7. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
Yassin A; Nettleship JE; Talib RA; Almehmadi Y; Doros G
Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589
[TBL] [Abstract][Full Text] [Related]
8. MANAGEMENT OF ENDOCRINE DISEASE: Rationale and current evidence for testosterone therapy in the management of obesity and its complications.
Lapauw B; Kaufman JM
Eur J Endocrinol; 2020 Dec; 183(6):R167-R183. PubMed ID: 33105105
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome.
Hackett G
Sex Med Rev; 2019 Jul; 7(3):476-490. PubMed ID: 30803918
[TBL] [Abstract][Full Text] [Related]
10. Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study.
Haider A; Yassin A; Haider KS; Doros G; Saad F; Rosano GM
Vasc Health Risk Manag; 2016; 12():251-61. PubMed ID: 27366080
[TBL] [Abstract][Full Text] [Related]
11. The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes.
Groti K; Žuran I; Antonič B; Foršnarič L; Pfeifer M
Aging Male; 2018 Sep; 21(3):158-169. PubMed ID: 29708829
[TBL] [Abstract][Full Text] [Related]
12. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study.
Traish AM; Haider A; Doros G; Saad F
Int J Clin Pract; 2014 Mar; 68(3):314-29. PubMed ID: 24127736
[TBL] [Abstract][Full Text] [Related]
13. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
[TBL] [Abstract][Full Text] [Related]
14. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints.
Permpongkosol S; Tantirangsee N; Ratana-olarn K
J Sex Med; 2010 Nov; 7(11):3765-74. PubMed ID: 20807330
[TBL] [Abstract][Full Text] [Related]
15. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies.
Saad F; Yassin A; Doros G; Haider A
Int J Obes (Lond); 2016 Jan; 40(1):162-70. PubMed ID: 26219417
[TBL] [Abstract][Full Text] [Related]
16. Waist circumference is superior to weight and BMI in predicting sexual symptoms, voiding symptoms and psychosomatic symptoms in men with hypogonadism and erectile dysfunction.
Yassin AA; Nettleship JE; Salman M; Almehmadi Y
Andrologia; 2017 May; 49(4):. PubMed ID: 27400881
[TBL] [Abstract][Full Text] [Related]
17. Effects of continuous long-term testosterone therapy (TTh) on anthropometric, endocrine and metabolic parameters for up to 10 years in 115 hypogonadal elderly men: real-life experience from an observational registry study.
Yassin AA; Nettleship J; Almehmadi Y; Salman M; Saad F
Andrologia; 2016 Sep; 48(7):793-9. PubMed ID: 26762680
[TBL] [Abstract][Full Text] [Related]
18. Effects of testosterone on Type 2 diabetes and components of the metabolic syndrome.
Jones TH
J Diabetes; 2010 Sep; 2(3):146-56. PubMed ID: 20923480
[TBL] [Abstract][Full Text] [Related]
19. Early weight loss predicts the reduction of obesity in men with erectile dysfunction and hypogonadism undergoing long-term testosterone replacement therapy.
Salman M; Yassin DJ; Shoukfeh H; Nettleship JE; Yassin A
Aging Male; 2017 Mar; 20(1):45-48. PubMed ID: 28084147
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
